Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Sells $172,033.46 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 36,838 shares of Precision BioSciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total transaction of $172,033.46. Following the completion of the sale, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at approximately $500,096.29. This trade represents a 25.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 4th, Michael Amoroso sold 3,012 shares of Precision BioSciences stock. The stock was sold at an average price of $8.19, for a total value of $24,668.28.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $5.08 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. The stock has a 50-day simple moving average of $5.46 and a two-hundred day simple moving average of $7.96. The firm has a market capitalization of $38.96 million, a PE ratio of 84.68 and a beta of 1.51. Precision BioSciences, Inc. has a 52-week low of $3.61 and a 52-week high of $19.43.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC boosted its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 65,974 shares of the company’s stock after acquiring an additional 19,088 shares during the period. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 at the end of the most recent quarter. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a report on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a report on Friday, January 10th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.